Literature DB >> 18451320

Computed tomography findings in acute exacerbation of idiopathic pulmonary fibrosis.

Masanori Akira1, Takenori Kozuka, Satoru Yamamoto, Mitsunori Sakatani.   

Abstract

RATIONALE: The serial computed tomography findings and prognosis of the acute exacerbation of idiopathic pulmonary fibrosis (IPF) are not yet well defined in a larger number of cases.
OBJECTIVES: To evaluate the parenchymal abnormalities and prognosis using high-resolution computed tomography (HRCT) in acute exacerbation of IPF.
METHODS: The study consisted of clinical, laboratory, and HRCT data before and at the time of acute exacerbation in 64 episodes of 58 patients with IPF. A semiquantitative analysis of overall extent of parenchymal abnormalities, extent of alveolar opacity (ground-glass attenuation and consolidation), and extent of fibrotic opacity (reticulation and honeycombing) on CT was performed by two chest radiologists. The newly appeared parenchymal abnormalities were also classified into three patterns: peripheral, multifocal, and diffuse.
MEASUREMENTS AND MAIN RESULTS: In all patients, HRCT scans taken at the exacerbation showed typical signs of IPF and newly developing alveolar opacity. They included 34 patients of peripheral pattern, 8 of multifocal pattern, and 16 of diffuse pattern. Twenty-five patients died and 33 survived after the initial exacerbation. Worse survival was associated with patients with diffuse type compared with patients with multifocal and peripheral type. The CT patterns and overall CT extent were associated with an increased hazard of death after adjusting for age, sex, smoking, baseline diffusion capacity for carbon monoxide, baseline FVC, and disease extent on CT. On multivariate analysis, the strongest correlations were observed between CT patterns (combined diffuse and multifocal versus peripheral) and survival (odds ratio, 4.629; 95% confidence interval, 1.900-11.278; P = 0.001).
CONCLUSIONS: HRCT extent and patterns are predictive of survival in acute exacerbation of IPF.

Entities:  

Mesh:

Year:  2008        PMID: 18451320     DOI: 10.1164/rccm.200709-1365OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  55 in total

1.  Pharmacological treatment of acute exacerbation of idiopathic pulmonary fibrosis: a retrospective study of 88 patients.

Authors:  Susumu Sakamoto; Hiroshige Shimizu; Takuma Isshiki; Atsuko Kurosaki; Sakae Homma
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2019-05-01       Impact factor: 0.670

2.  Acute exacerbation of idiopathic pulmonary fibrosis: high-resolution CT scores predict mortality.

Authors:  Kiminori Fujimoto; Hiroyuki Taniguchi; Takeshi Johkoh; Yasuhiro Kondoh; Kazuya Ichikado; Hiromitsu Sumikawa; Takashi Ogura; Kensuke Kataoka; Takahiro Endo; Atsushi Kawaguchi; Nestor L Müller
Journal:  Eur Radiol       Date:  2011-08-07       Impact factor: 5.315

3.  Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Proposal.

Authors:  Kerri Johannson; Harold R Collard
Journal:  Curr Respir Care Rep       Date:  2013-12

Review 4.  Acute exacerbation of idiopathic pulmonary fibrosis-a review of current and novel pharmacotherapies.

Authors:  Maya M Juarez; Andrew L Chan; Andrew G Norris; Brian M Morrissey; Timothy E Albertson
Journal:  J Thorac Dis       Date:  2015-03       Impact factor: 2.895

Review 5.  High-resolution CT of complications of idiopathic fibrotic lung disease.

Authors:  C R Lloyd; S L F Walsh; D M Hansell
Journal:  Br J Radiol       Date:  2011-07       Impact factor: 3.039

6.  Visual classification of three computed tomography lung patterns to predict prognosis of COVID-19: a retrospective study.

Authors:  Daisuke Yamada; Sachiko Ohde; Ryosuke Imai; Kengo Ikejima; Masaki Matsusako; Yasuyuki Kurihara
Journal:  BMC Pulm Med       Date:  2022-01-03       Impact factor: 3.317

7.  An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.

Authors:  William D Travis; Ulrich Costabel; David M Hansell; Talmadge E King; David A Lynch; Andrew G Nicholson; Christopher J Ryerson; Jay H Ryu; Moisés Selman; Athol U Wells; Jurgen Behr; Demosthenes Bouros; Kevin K Brown; Thomas V Colby; Harold R Collard; Carlos Robalo Cordeiro; Vincent Cottin; Bruno Crestani; Marjolein Drent; Rosalind F Dudden; Jim Egan; Kevin Flaherty; Cory Hogaboam; Yoshikazu Inoue; Takeshi Johkoh; Dong Soon Kim; Masanori Kitaichi; James Loyd; Fernando J Martinez; Jeffrey Myers; Shandra Protzko; Ganesh Raghu; Luca Richeldi; Nicola Sverzellati; Jeffrey Swigris; Dominique Valeyre
Journal:  Am J Respir Crit Care Med       Date:  2013-09-15       Impact factor: 21.405

Review 8.  Determinants of initiation and progression of idiopathic pulmonary fibrosis.

Authors:  Robert Matthew Kottmann; Christopher M Hogan; Richard P Phipps; Patricia J Sime
Journal:  Respirology       Date:  2009-09       Impact factor: 6.424

9.  Staging of acute exacerbation in patients with idiopathic pulmonary fibrosis.

Authors:  Tomoo Kishaba; Hitoshi Tamaki; Yousuke Shimaoka; Hajime Fukuyama; Shin Yamashiro
Journal:  Lung       Date:  2013-11-13       Impact factor: 2.584

10.  CT Imaging Phenotypes of Pulmonary Fibrosis in the MUC5B Promoter Site Polymorphism.

Authors:  Jonathan H Chung; Anna L Peljto; Ashish Chawla; Janet L Talbert; David F McKean; Byung-Hak Rho; Tasha E Fingerlin; Marvin I Schwarz; David A Schwartz; David A Lynch
Journal:  Chest       Date:  2016-01-13       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.